» Articles » PMID: 11566551

Nitric Oxide Production in Caco-2 Cells Exposed to Different Inducers, Inhibitors and Natural Toxins

Overview
Specialty Toxicology
Date 2001 Sep 22
PMID 11566551
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The involvement of the NO pathway in several intestinal inflammatory diseases is under investigation. In vitro models may provide a useful approach to better characterise this pathway at the cellular level. For this purpose, we have used Caco-2 cells, which are able to spontaneously differentiate in long-term culture to small intestine enterocytes. The effect of different NO pathway inducers [gamma-interferon (IFN-gamma) and phorbol myristate acetate (PMA)] has been studied. Our results demonstrate that Caco-2 cells constitutively express NOS at very low levels, while the induction with PMA+IFN-gamma triggers the expression of the inducible isoform with a stronger effect starting from day 14 of differentiation. The use of specific inhibitors of gene expression, at transcriptional and translational level, suggests that new synthesis of iNOS mRNA is required, through direct activation of the gene or new synthesis of transcription-required factors, as indicated by CHX inhibition. The morphological alteration induced by PMA+IFN-gamma is reversed by iNOS inhibitor, suggesting that the NO pathway may be involved in the cytoskeletal alterations. The DSP toxins, OA and DTX-1, induce NO production at levels corresponding to their different toxicity, previously detected in Caco-2 cells.

Citing Articles

Uptake and Immunomodulatory Properties of Betanin, Vulgaxanthin I and Indicaxanthin towards Caco-2 Intestinal Cells.

Wang Y, Fernando G, Sergeeva N, Vagkidis N, Chechik V, Do T Antioxidants (Basel). 2022; 11(8).

PMID: 36009345 PMC: 9405451. DOI: 10.3390/antiox11081627.


Gut microbial transcytosis induced by tumor necrosis factor-like 1A-dependent activation of a myosin light chain kinase splice variant contributes to IBD.

Pai Y, Weng L, Wei S, Wu L, Shih D, Targan S J Crohns Colitis. 2020; .

PMID: 32770194 PMC: 7904084. DOI: 10.1093/ecco-jcc/jjaa165.


A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: Toward applications for Crohn's disease.

McKay R, Ghodasra M, Schardt J, Quan D, Pottash A, Shang W Bioeng Transl Med. 2018; 3(3):209-221.

PMID: 30377661 PMC: 6195910. DOI: 10.1002/btm2.10113.


Development of Cell-Based Sentinels for Nitric Oxide: Ensuring Marker Expression and Unimodality.

McKay R, Hauk P, Quan D, Bentley W ACS Synth Biol. 2018; 7(7):1694-1701.

PMID: 29975512 PMC: 7025431. DOI: 10.1021/acssynbio.8b00146.


An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin.

Elliott T, Guildford A Int J Inflam. 2017; 2017:5968618.

PMID: 28676841 PMC: 5476893. DOI: 10.1155/2017/5968618.